Zealand Pharma A/S' obesity drug pipeline, including petrelintide, shows promise but faces high risks. Click to explore ZLDPF ...

But while analysts saw Roche as an early contender for petrelintide, both firms insisted it was by no means a done deal. "It was a very competitive process, with a number of parties until the end ...